Here is all you need to know about Mankind Pharma IPO:
Mankind Pharma IPO
Mankind Pharma Limited is a leading Indian pharmaceutical company that develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products. The company was incorporated in 1991 and has since grown to become one of the largest pharmaceutical companies in India.
Financial Performance
In terms of financial performance, Mankind Pharma has shown consistent growth in revenue and profits over the past few years. For the financial year 2021-22, the company reported a total revenue of ₹7,977.58 crores and a net profit of ₹1,452.96 crores. This represents a growth of 17.5% and 23.3%, respectively, over the previous financial year.
Profitability Ratios
- P/E (Price-to-Earnings) Ratio: 32.5
- ROE (Return on Equity): 27.6%
- ROCE (Return on Capital Employed): 26.1%
- EPS (Earnings per Share): ₹33.2
- RoNW (Return on Net Worth): 27.7%
Manufacturing and Distribution
Mankind Pharma has a pan-India marketing presence, with a field force of 11,691 medical representatives and 3,561 field managers, as of December 31, 2022. The company operates 25 manufacturing facilities across India and had 4,121 manufacturing personnel as of December 31, 2022. It has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market.
Products
The company has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among them. It is active in a number of acute and chronic therapeutic fields, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.
Industry and Competition
The Indian pharmaceutical industry is highly competitive, with a large number of domestic and multinational companies operating in the market. Mankind Pharma competes with other leading Indian pharmaceutical companies such as Sun Pharmaceutical Industries, Cipla, Lupin, Dr. Reddy’s Laboratories, and others. Despite the competition, Mankind Pharma has managed to maintain its position as one of the leading pharmaceutical companies in India, with a strong presence across various therapeutic areas.
IPO Details
- Mankind Pharma Limited is going public with a Book Built Issue IPO of 40,058,844 equity shares of a face value of ₹1 each, aggregating up to ₹4,326.36 crores.
- The IPO will be open for subscription from April 25, 2023, to April 27, 2023.
- The price band for the IPO has been fixed at ₹1026 to ₹1080 per share.
- The lot size for the IPO is 13 shares.
- The shares will be listed on both the BSE and NSE.
- The company’s promoters are Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Ramesh Juneja Family Trust, Rajeev Juneja Family Trust, and Prem Sheetal Family Trust.
- The company will not receive any proceeds from the offer, and all the offer proceeds will be received by the selling shareholders, in proportion to the offered shares sold by the respective selling shareholders as part of the offer.
Should You Subscribe to Mankind Pharma IPO?
Based on the financial performance, manufacturing and distribution capabilities, product portfolio, and industry position, Mankind Pharma appears to be a strong player in the Indian pharmaceutical market. However, potential investors should carefully evaluate the risks associated with the IPO, including market and industry risks, before making an investment decision. It is recommended that investors do their own research and consult with a financial advisor before investing in the IPO.